Medical technology firm ImpediMed (ASX:IPD) appointed Erik Anderson as Managing Director and CEO, effective April 7.
Anderson succeeds Dr Parmjot Bains, who will remain with the company as an adviser until June 30 to ensure a seamless leadership transition.
The leadership change comes at a pivotal moment for ImpediMed. Under Dr Bains' tenure, the company broadened its market presence, most notably expanding its SOZO platform and achieving 93% reimbursement coverage for breast cancer-related lymphoedema in the US.
With the operational foundations now firmly established, the board has turned to Anderson to lead a "step change" in commercial execution and revenue growth.
Anderson joins the company with a formidable pedigree in the US medtech sector. He most recently served as division president at Hologic, where he oversaw the Breast and Skeletal Health business.
His expertise spans the entire clinical continuum—from detection to surgery—and includes a proven track record in hospital procurement and clinical adoption.
Board Chair Christine Emmanuel-Donnelly expressed confidence that Anderson’s deep engagement with US health systems will be instrumental in driving the next phase of growth.
At the time of reporting, ImpediMed’s share price was $0.016.